DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Maio M, Grob JJ, Aamdal S. et al.
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial.
J Clin Oncol 2015;
33: 1191-1196
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.